Appetite Regulation

Appetite Regulation

Appetite regulation is governed by a highly integrated system of peripheral hormonal signals, central nervous system circuits, and gastrointestinal feedback mechanisms that collectively determine hunger, satiety, and overall energy intake. Key hormones involved in this process include ghrelin, which is secreted by the stomach and stimulates appetite, and anorexigenic hormones such as leptin (produced by adipose tissue), peptide YY (PYY), cholecystokinin (CCK), and the incretin hormones GLP-1 and GIP, which promote satiety and reduce food intake. These peripheral signals converge on hypothalamic nuclei, particularly the arcuate nucleus, where they modulate the activity of orexigenic (appetite-stimulating) neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP), as well as anorexigenic neurons expressing pro-opiomelanocortin (POMC).

The brainstem, specifically the nucleus of the solitary tract (NTS), also plays a critical role by integrating vagal afferent signals from the gastrointestinal tract that relay information about gastric distension, nutrient content, and gut hormone release. Hedonic or reward-driven eating, mediated by dopaminergic pathways in the mesolimbic system, adds another layer of complexity to appetite regulation that can override homeostatic signals. Disruption of these regulatory pathways contributes to the development and persistence of obesity, making them attractive therapeutic targets.

Clinical Relevance to Retatrutide

Retatrutide exerts its weight-lowering effects in part through potent modulation of appetite regulatory pathways. As a GLP-1 receptor agonist, retatrutide activates central anorexigenic circuits and delays gastric emptying, leading to enhanced satiety and reduced caloric intake. The additional GIP and glucagon receptor agonism may further influence appetite through distinct but complementary mechanisms, including modulation of reward signaling and energy expenditure. In clinical trials, participants treated with retatrutide reported meaningful reductions in hunger and food consumption, consistent with multi-receptor engagement of the appetite regulation system.